1 Introduction
2 Related Work
3 Methodology
Figure 1. Conceptual sketch of methodology. |
4 Results and Discussion
4.1 Overview
Table 1 MeSH LDA results ranked by popularity. |
Year | 1st topic | 2nd topic | 3rd topic | 4th topic | 5th topic |
---|---|---|---|---|---|
All (1945-2015) | Huntington disease Parkinson disease Neurons Cerebral coretex Nerve tissue proteins | Mental disorders Caregivers Dementia, vascular AIDS dementia complex Schizophrenia | Tau proteins Amyloid beta-protein precursor Neurodegenerative diseases Brain diseases Amyloid | Aging Cognition Cholinesterase inhibitors Memory disorders Neuropsychological tests | Creutzfeldt-Jakob syndrome Apolipoproteins E Magnetic resonance imaging Nursing homes Genetic predisposition to disease |
1995-2004 | Creutzfeldt-Jakob syndrome Apolipoproteins E Huntington disease Tau proteins Magnetic resonance imaging | Amyloid beta-protein precursor Neurons Membrane proteins Nerve tissue proteins Neurodegenerative diseases | Parkinson disease Caregivers Neuropsychological tests Cognition Memory | Cholinesterase inhibitors Dementia, vascular Memory disorders Nootropic agents Schizophrenia | AIDS dementia complex Aging Peptide fragments HIV-1 HIV infections |
2005-2014 | Neurons Peptide fragments Tau proteins Amyloid beta-protein precursor Huntington disease | Aging Neuropsychological tests Magnetic resonance imaging Memory disorders Memory | Cognition Neurodegenerative diseases Mental disorders Nursing homes Amyotrophic lateral sclerosis | Parkinson disease Caregivers Amyloid Creutzfeldt-Jakob syndrome Depression | Cholinesterase inhibitors Neuroprotective agents Dementia, vascular Frontotemporal dementia Amyloid precursor protein secretases |
Table 2 Gene LDA results ranked by popularity. |
Year | 1st topic | 2nd topic | 3rd topic | 4th topic | 5th topic |
---|---|---|---|---|---|
All (1945-2015) | APP TNF BDNF BACE1 NGF | APOE BCHE CAT CA3 CA1 | INS HTT PSEN1 CA1 APP | MS PRNP GFAP ALB MDD1 | MAPT SDS SST GRN PSD |
1995-2004 | APP MS CD4 SPY PSEN1 | APOE BDNF ACT A2M LDLR | PRNP INS NGF TF TTR | TNF PSEN1 GFAP MAPT BCHE | HTT CA1 SDS ALB CA3 |
2005-2014 | APOE INS TNF APP ACE | APP GFAP CD4 CAT NOTCH3 | HTT PRNP CA1 BACE1 NGF | MS BDNF MAPT BCHE SYP | PSEN1 APP APOE ALB PSEN2 |
4.2 Question Answering Examples
Table 3 Question answering example: What is Huntington’s disease? |
Question | Answer example |
---|---|
What is Huntington’s disease? | an inherited neurodegenerative disorder (44) a neurodegenerative disorder (28) a hereditary brain disease (2) an incurable genetic neurodegenerative disorder (1) a complex, single gene (1) (wrong extraction) |
Table 4 What are CJS, MRI, APP, and APOE? |
Term | Definition |
---|---|
AD | a neurodegenerative disorder |
AD | a genetically complex and heterogeneous disorder |
CJS | a rare neurodegenerative disease |
CJS | a fatal neurodegenerative illness |
CJS | an incurable disease |
MRI | a useful diagnostic marker |
MRI | a promising AD biomarker |
MRI | the most widely used and less invasive medical imaging technique |
APP | a transmembrane glycoprotein |
APP | an extremely complex molecule |
APP | the key player in AD pathogenesis |
APOE | the major apolipoprotein |
APOE | the only confirmed susceptibility gene for AD |
APOE | the most prevalent and best established genetic risk factor for late-onset AD. |
Figure 2. Two-step paths from AD to HD. |
Figure 3. Two-step paths from AD to HIV. |